Vivus Would Market Qnexa With Pregnancy Category X Designation If Approved

With a strict REMS its only possible future, the weight-loss drug is unaffected by FDA decision to reclassify the topiramate portion of the combination drug as Pregnancy Category D.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet